Article Type
Review
Published
This is a critical narrative review focusing on HR+/human epidermal growth factor receptor 2-negative (HER2–) de novo metastatic breast cancer in terms of genomic, biological, pathological, and clinical features and outcomes after systemic and locoregional treatments, outlining differences with recurrent metastatic breast cancer.